Complement component C9 enhances the capacity of beta-lactam antibiotics to kill Escherichia coli in vitro and in vivo

American Journal of the Medical Sciences

Volumn 315, Issue 5, 1998, Pages 307-313

  Jung, Elizabeth ^a   Feldhoff, Richard C ^a   Walz, Brent M ^a   Drehs, Molly M ^a   Buchheit, John Q ^a   Lassiter, Herbert A ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Beta lactam antibiotics; Complement component C9; Escherichia coli; Neonate; Sepsis

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; COMPLEMENT COMPONENT C9;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLONY FORMING UNIT; COMPLEMENT BLOOD LEVEL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG POTENTIATION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNOELECTROPHORESIS; INTRAPERITONEAL DRUG ADMINISTRATION; NEWBORN; NEWBORN SEPSIS; NONHUMAN; RAT; SERUM BACTERICIDAL ACTIVITY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031958316     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199805000-00004     Document Type: Article

References (30)

1. Klein JO, Marcy SM. Bacterial sepsis and meningitis. In: Remington JS, Klein JO; eds. Infectious Diseases of the Fetus and Newborn Infant, 4th ed. Philadelphia: WB Saunders; 1995:835-90.
2. Roantree RJ, Rantz LA. A study of the relationship of the normal bactericidal activity of human serum to bacterial infection. J Clin Invest. 1960;39:72-81.
3. Vosti KI, Randall E. Sensitivity of serologically classified strains of Escherichia coli of human origin to the serum bactericidal system. Am J Med Sci. 1970;259:114-9.
4. Fierer J, Finley F, Braude AI. A plaque assay on agar for detection of gram negative bacilli sensitive to complement. J Immunol. 1972;109:1156-8.
5. Taylor PW. Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. Microbiol Rev. 1983;47:46-83.
6. Morgan BP. The complement system. In: Complement: Clinical Aspects and Relevance to Disease. New York: Academic Press; 1990:1-35.
7. Lassiter HA, Wilson JL, Feldhoff RC, Hoffpauir JM, Kleuber KM. Supplemental complement component C9 enhances the capacity of neonatal serum to kill multiple isolates of pathogenic Escherichia coli. Pediatr Res. 1994;35:389-96.
8. Lassiter HA, Walz BM, Wilson JL, Jung E, Calisi CR, Goldsmith LJ, et al. The administration of complement component C9 enhances the survival of neonatal rats with Escherichia coli sepsis. Pediatr Res. 1997;42(1):128-35.
9. Mandell GL, Sande MA. Antimicrobial agents: Penicillins, cephalosporins, and other beta-lactam antibiotics. In: Gilman AG, Rail TW, Nies AS, Taylor P; eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. New York: Pergamon Press; 1990:1065-97.
10. Biesecker G, Müller-Eberhard HJ. The ninth component of complement: Purification and physiochemical characterization. J Immunol. 1980;124:1291-6.
11. Esser AF, Sodetz JM. Membrane attack complex proteins C5b-6, C7, C8, and C9 of human complement. Methods Enzymol. 1988;162:551-78.
12. Feldhoff RC, Walz BM, Calisi CR, Kim J, Lassiter HA. Complement component C9: Improved purification method and utilization in studies of neonatal C9 deficiency (abstract 682). FAESB J. 1995;39:296a.
13. 2-ethylene glycoltetraacetic acid. Infect Immun. 1975;11:1235-43.
14. Kolb WP, Haxby JA, Arroyave CM, Müller-Eberhard HJ. Molecular analysis of the membrane attack complex of complement. J Exp Med. 1972;135:549-66.
15. Goldman NJ, Austen KF. Reaction mechanisms of the nascent C567 (reactive lysis). II. Killing of a rough form of Escherichia coli by C567, C8, and C9. J Infect Dis. 1974;129:444-50.
16. Podack ER, Tschopp J, Müller-Eberhard HJ. Molecular organization of C9 within the membrane attack complex of complement: Induction of circular C9 polymerization by the C5b-8 assembly. J Exp Med. 1982;156:268-82.
17. Tschopp J, Podack ER, Müller-Eberhard HJ. Ultrastructure of the membrane attack complex of complement: Detection of the tetramolecular C9-polymerizing complex C5b-8. Proc Natl Acad Sci USA. 1982;79:7474-8.
18. Esser AF. The membrane attack complex of complement. Year Immunol. 1990;6:229-44.
19. MacKay SL, Dankert JR. Bacterial killing and inhibition of inner membrane activity by C5b-9 complexes as a function of the sequential addition of C9 to C5b-8 sites. J Immunol. 1990;145:3367-71.
20. Taylor PW, Gaunt H, Unger FM. Effect of subinhibitory concentrations of mecillinam on the serum susceptibility of Escherichia coli strains. Antimicrob Agents Chemother. 1981;19:786-8.
21. Wiemer CWC, Kubens B, Opferkuch W. Influence of imipenem on the serum resistance of Enterobacteriaceae. Rev Infect Dis. 1985;7(suppl 3):s426-31.
22. Schweinle JE, Nishiyasu M. Sub-minimal inhibitory concentrations of cefmetazole enhance serum bactericidal activity in vitro by amplifying poly-C9 deposition. J Clin Invest. 1992;89:1198-1207.
23. Darveau RP, Cunningham MD. Influence of subinhibitory concentrations of cephalosporins on the serum sensitivity of Pseudomonas aeruginosa. J Infect Dis. 1990;162:914-21.
24. von Zabern I, Przyklenk H, Nolte R, Vogt W. Effect of different penicillin derivatives on complement components in human serum. Int Arch Allergy Immunol. 1984;75(2):164-72.
25. Sweetman RW, Cairo MS. Blood component and immunotherapy in neonatal sepsis. Transfusion Med Rev. 1995; 9:251-9.
26. Christensen RD, Rothstein G, Anstall HB, Bybee B. Granulocyte transfusions in neonates with bacterial infection, neutropenia, and depletion of mature marrow neutrophils. Pediatrics. 1982;70:1-6.
27. Gillan E, Christensen RD, Suen Y, Ellis R, van de Ven C, Cairo MS. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: Significant induction of peripheral and bone marrow neutrophilia. Blood. 1994;84:1427-33.
28. Lassiter HA. Intravenous immunoglobulin in the prevention and treatment of neonatal bacterial sepsis. Adv Pediatr 1992;39:71-99.
29. Mitchell TJ, Naughton M, Norsworthy P, Davies KA, Walport MJ, Morley BJ. Interferon-δ upregulates expression of C3 and C4 by stabilization of mRNA (abstract 276). Mol Immunol. 1996;33(suppl 1):69.
30. O'Hara LC, McCarty SC, Lassiter HA, Feldhoff RC. Complement component C9: Nucleotide sequence of rat C9 cDNA: Interspecies comparisons of amino acid sequences (abstract 328). 1996;33(suppl 1):82.